ProfileGDS5678 / 1456846_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 59% 60% 49% 60% 61% 59% 58% 61% 60% 61% 64% 60% 60% 60% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.5623759
GSM967853U87-EV human glioblastoma xenograft - Control 23.6138360
GSM967854U87-EV human glioblastoma xenograft - Control 33.1704949
GSM967855U87-EV human glioblastoma xenograft - Control 43.5505560
GSM967856U87-EV human glioblastoma xenograft - Control 53.621161
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6258759
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6009958
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.6514961
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5632760
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6105761
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8256864
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5868160
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.5957760
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5955860